Stockscreener 앱 받기
34.29
49.34%
-33.40
시장 영업 전:
32.09
-2.20
-6.42%
Uniqure N V 주식(QURE)의 최신 뉴스
Risk adjusted return profile for uniQure N.V. analyzedJuly 2025 Spike Watch & High Return Trade Opportunity Guides - newser.com
Is uniQure N.V. stock a bargain at current levelsJuly 2025 WrapUp & Precise Entry and Exit Recommendations - newser.com
PreBLA Meeting With FDA Sinks uniQure’s Hopes for Approval of Huntington Disease Gene Therapy AMT-130 Based Primarily on Phase 1/2 Data - CGTLive®
FDA’s rebuff of uniQure raises uncertainty over external control standards - BioCentury
How FDA’s Revised Stance on AMT-130 Data Has Changed uniQure’s (QURE) Investment Story - simplywall.st
uniQure (QURE) Maintains Buy Rating as Chardan Capital Lowers Pr - GuruFocus
UniQure Reeling As FDA Reverses Stance On Accelerated Approval For AMT-130 - Citeline News & Insights
UniQure Shares Dive After ‘Surprising’ Pivot by FDA on Drug Data - Bloomberg.com
QURE Investor ALERT: Block & Leviton Investigating uniQure for Securities Fraud; Investors ... - Bluefield Daily Telegraph
QURE Investor ALERT: Block & Leviton Investigating uniQure - GlobeNewswire
INVESTOR ALERT: Investigation of uniQure N.V. (QURE) Announced by Holzer & Holzer, LLC - GlobeNewswire
Why UniQure Stock Is Plunging TodayuniQure (NASDAQ:QURE) - Benzinga
uniQure N.V. (QURE) Stock: Plunges 57% After Unexpected FDA Setback on AMT-130 - CoinCentral
QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with the Schall Law Firm - The AI Journal
uniQure (QURE) Shares Plunge Over 50% - GuruFocus
uniQure (QURE) Faces Setback with FDA on AMT-130 BLA Submission - GuruFocus
H.C. Wainwright Maintains UniQure NV(QURE.US) With Buy Rating, Maintains Target Price $110 - 富途牛牛
UniQure shares plummet as FDA says inadequate clinical data for Huntington's therapy - Reuters
UniQure stock crashes over 50% today after FDA says Huntington’s therapy data isn’t enoughhere's what i - The Economic Times
uniQure Stock Tumbled 55% Today: What’s The FDA Angle? - Stocktwits
uniQure (QURE) Price Targets Raised by Analysts After Positive Trial Results - MSN
uniQure stock falls after FDA feedback on gene therapy application - Seeking Alpha
uniQure (QURE) Faces FDA Reversal on AMT-130 Phase 1/2 Data - GuruFocus
Uniqure stock plunges after FDA rejects company’s clinical data for Huntington's therapy - Proactive financial news
uniQure (QURE) Shares Plummet Over 57% - GuruFocus
UniQure (QURE) Stock: Biotech Plunges 67% After FDA Reverses Position on Gene Therapy Data - parameter.io
UniQure Shares Fall Sharply as Trading Resumes After Volatility Halt - MarketScreener
uniQure N.V. Investigated for Securities Fraud ViolationsContact the DJS Law Group to Discuss Your Rights – QURE - The Globe and Mail
UniQure Stock Plummets 67% on Potential FDA Decision. Here's Why. -- Barrons.com - 富途牛牛
Top Premarket Decliners - 富途牛牛
How analysts rate uniQure N.V. stock today2025 Analyst Calls & Real-Time Buy Zone Alerts - newser.com
uniQure Shares Collapse 75% After FDA Reverses Position on Huntington’s Therapy - MSN
UniQure’s FDA submission for its Huntington’s disease therapy thrown into question - statnews.com
Predicting uniQure N.V. trend using moving averagesQuarterly Trade Review & Long-Term Growth Portfolio Plans - newser.com
UniQure Shares Fall Pre-Bell After FDA Raises Questions on Huntington's Disease Therapy Data - MarketScreener
uniQure (QURE) Faces Unexpected FDA Feedback on AMT-130 Gene The - GuruFocus
uniQure Faces FDA Setback on Huntington’s Therapy - TipRanks
Is uniQure N.V. stock trading at a premium valuationJuly 2025 Catalysts & Verified Momentum Stock Ideas - newser.com
FDA says clinical data for UniQure's Huntington's disease therapy not adequate - MarketScreener
uniQure stock plummets after FDA shifts stance on Huntington’s therapy By Investing.com - Investing.com Nigeria
uniQure N.V. Provides Regulatory Update on AMT-130 for Huntington's Disease - TradingView
Can uniQure N.V. stock hit analyst price targetsTrade Exit Summary & Safe Entry Zone Identification - newser.com
uniQure stock plummets after FDA shifts stance on Huntington’s therapy - Investing.com
uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease - Yahoo Finance
uniQure N.V. stock outlook for YEARJuly 2025 Reactions & High Yield Stock Recommendations - newser.com
What data driven models say about uniQure N.V.’s future2025 Growth vs Value & High Accuracy Buy Signal Tips - newser.com
uniQure N.V. (NASDAQ:QURE) Short Interest Down 31.4% in October - MarketBeat
What catalysts could drive uniQure N.V. stock higherJuly 2025 PreEarnings & Capital Efficient Trade Techniques - newser.com
Can uniQure N.V. (UQ1) stock sustain revenue momentumWatch List & Stepwise Trade Signal Guides - newser.com
Can uniQure N.V. stock hit record highs againTrade Exit Summary & Free Safe Entry Trade Signal Reports - newser.com
Jennison Associates LLC Acquires Shares of 140,060 uniQure N.V. $QURE - MarketBeat
0.64%
0.35%
자본화:
|
볼륨(24시간):